Weekly shot shows promise for obesity and diabetes
NCT ID NCT06567041
First seen Nov 01, 2025 · Last updated May 22, 2026 · Updated 32 times
Summary
This early-stage study tested a new medicine, NNC0519-0130, given as a weekly shot. The goal was to check its safety and how it affects body weight and blood sugar in 82 adults with obesity or type 2 diabetes. Participants received either the drug or a placebo for up to 37 weeks. The study is complete, and results will help guide future research.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OBESITY are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Parexel International GmbH
Berlin, 14050, Germany
Conditions
Explore the condition pages connected to this study.